A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Can-Fite BioPharma.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Can-Fite BioPharma
ClinicalTrials.gov Identifier:
NCT00837291
First received: February 3, 2009
Last updated: February 8, 2012
Last verified: February 2012

February 3, 2009
February 8, 2012
November 2011
December 2012   (final data collection date for primary outcome measure)
Proportion of responders by OMERACT-OARSI definition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00837291 on ClinicalTrials.gov Archive Site
  • Safety, as assessed through vital signs, physical examinations, adverse event reporting, clinical laboratory testing, and ECGs [ Time Frame: 14 weeks ] [ Designated as safety issue: Yes ]
  • Change from baseline in total WOMAC score, and pain, physical function, and stiffness subscale scores [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in physician's and patient's global assessments [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Daily CF101 Administered Orally for 12 Weeks to Patients With Osteoarthritis of the Knee

This study will test the effectiveness of CF101 in treating the symptoms of osteoarthritis (OA) of the knee. Eligible patients will be given either CF101 or matching placebo tablets and their symptoms will be evaluated over the 12 week treatment period.

This will be a randomized, double-blind, placebo-controlled, parallel-group study in which patients with knee OA will be randomized to either CF101 1 mg or matching placebo tablets every 12 hours and followed for 12 weeks on treatment. For patients with bilateral knee involvement, only 1 knee will be selected for evaluation, namely, the most severely involved knee that meets study criteria (the "index knee"). Screening examinations will occur within 1 month prior to dosing. Washout of non-specific non-steroidal anti-inflammatory drugs (nsNSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors will occur prior to dosing, and must be followed by requalification before dosing. Disease activity will be assessed using changes from baseline in Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) scores, and the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and subscales for pain, physical function, stiffness, according to the Outcome Measures in Rheumatology Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, 12, and 14.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Osteoarthritis of the Knee
  • Drug: CF101
    CF101 tablets 1 mg BID
    Other Name: IB-MECA
  • Drug: Placebo
    Placebo tablets BID
    Other Name: Inactive tablets
  • Experimental: CF101 1 mg BID
    Intervention: Drug: CF101
  • Placebo Comparator: Placebo
    Placebo tablets BID
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
188
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females age 40 years or above
  • Clinical evidence of knee OA, as indicated by:

    • Pain requiring treatment with NSAID or coxib medication for analgesia for at least 6 months prior to the screening visit, and
    • Pain requiring treatment with NSAID or coxib medication for analgesia on the majority of days during the preceding month
  • Radiographic evidence of knee OA, as indicated by findings of Kellgren-Lawrence Grade 2 or 3 within 1 year prior to the screening visit2
  • American College of Rheumatology functional class I, II, or III3
  • WOMAC pain subscale score ≥40 mm at baseline
  • WOMAC function subscale score >20 mm at baseline
  • PGA >10 mm at baseline
  • In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
  • Negative screening serum pregnancy test for female patients of childbearing potential
  • Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)
  • All aspects of the protocol explained and written informed consent obtained

Exclusion Criteria:

  • Predominant patellofemoral disease
  • Concomitant local or systemic inflammatory arthropathy which could confound evaluation of the knee
  • Ipsilateral hip or extremity disease which could confound evaluation of the knee
  • History of clinical significant trauma or surgery to the index knee
  • Arthroscopy to the index knee within 6 months prior to the screening visit
  • Corticosteroid, hyaluronic acid, or other intraatricular injection to the index knee within 3 months prior to the screening visit
  • Use of chondroitin sulfate and/or glucosamine, or diacerin, within 2 weeks prior to the screening visit
  • Concomitant requirement for NSAID, coxib medication, or opioid analgesics (acetaminophen is allowed)
  • Use of systemic corticosteroids >10 mg/d of prednisone, or equivalent
  • Presence or history of uncontrolled arterial hypertension or symptomatic hypotension
  • Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of clinically significant heart disease; other clinically significant findings on screening electrocardiogram (ECG)
  • Hemoglobin level <10.0 gm/dL at the screening visit
  • White blood cell count <3000/mm3 at the screening visit
  • Platelet count <125,000/mm3 at the screening visit
  • Serum creatinine level outside the central laboratory's normal limits at the screening visit
  • Liver aminotransferase (ALT and/or AST) levels greater than the upper limit of normal at the screening visit
  • Known or suspected immunodeficiency or human immunodeficiency virus positivity
  • Pregnancy, lactation, or inadequate contraception as judged by the Investigator
  • Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to screening
  • History of drug or alcohol dependence
  • History of malignancy within the past 5 years (excluding excised basal or squamous cell carcinoma of the skin)
  • Diagnosis of Parkinson's Disease
  • Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
Both
18 Years to 90 Years
No
Contact: Sari Fishman, Ph.D. +972-3-9241114 sari@canfite.co.il
Israel
 
NCT00837291
CF101-221OA
Yes
Michael H Silverman, MD, FACP, Medical Director, Can-Fite BioPharma
Can-Fite BioPharma
Not Provided
Study Director: Michael H Silverman, MD Can-Fite BioPharma Ltd
Can-Fite BioPharma
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP